<DOC>
	<DOC>NCT00633464</DOC>
	<brief_summary>The purpose of this study was to estimate the response rate of ixabepilone monotherapy, and the combination of ixabepilone plus cetuximab as first-line treatment of female subjects with triple negative (estrogen receptor [ER], progesterone receptor [PR], Human Epidermal Growth Factor Receptor 2 [HER2] negative) locally advanced non-resectable and/or metastatic breast cancer</brief_summary>
	<brief_title>Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Female subjects with triple negative (ER, PR, and HER2 negative) locally advanced nonresectable and/or metastatic breast cancer Prior adjuvant or neoadjuvant anthracyclinebased chemotherapy Tumors that are fluorescence in situ hybridization test (FISH) positive or immunohistochemistry (IHC) 3+ Neuropathy &gt; Grade 1 Prior systemic therapy for metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>